W-INITIATIVE
1.6.2022 13:27:08 CEST | Business Wire | Press release
Norway’s best tennis player and superstar Casper Ruud (23) is the new global ambassador for the Norwegian humanitarian foundation W Initiative. The agreement involves a close partnership over the next three years.
W Initiative was established in 2021 by SalMar heir Gustav Magnar Witzoe (29), to support humanitarian activities that improve the quality of life for children and young people around the world.
“I am proud to promote W Initiative on an international arena. I can think of nothing more meaningful than to help children and young people have a better live, better health and more equal opportunities, which also includes games and sports,” says Casper Ruud, who is currently competing in the French Open Grand Slam tournament.
Long-term partnership
As ambassador, Casper Ruud will be promoting the foundation and making it more visible to an international audience. This includes wearing the W Initiative logo on his clothing, talking about the foundation’s work during interviews, in social media and on his own website, as well as participating in various events organised by the foundation. The goal for the W Initiative is to be more visible and, consequently, receive information about and access to new projects around the world that it can support.
“The foundation actively searches for projects around the world that align with key sustainability goals. Having Casper Ruud as an ambassador will open more doors and we can reach international audiences in a completely different way,” explains Managing Director of the foundation Eirik Boe Sletten.
Gustav Magnar Witzoe created W Initiative in 2021 and it is Witzoe’s company Forward Project that is funding the partnership with Casper Ruud, which starts on 1 June and lasts until the end of 2024. W Initiative will then have the preferential right to extend the partnership for another two years.
The right man
“When I first met Casper, it was immediately clear that he was the right ambassador for the foundation – not only because he is one of the world’s best athletes who plays on the world’s premiere arenas, but also because he is simply a great guy who shares the foundation’s values and views. His contribution comes at an important time in the evolution of the foundation. If this partnership can also contribute positively to his own development as Norway’s best tennis player, that’s fantastic,” says Witzoe.
Witzoe comes from a small rural Island off the west coast of Norway with a population of just over 4000. His father pioneered the fish farming industry, in time becoming one of the world’s most successful in the industry, with his company SalMar.
W Initiative aims to grow through effective management and expansion to make increasingly meaningful contributions.
“Our first project in Uganda, which is being carried out together with Right To Play, contributes to better water and sanitary conditions, in addition to games and sports for children in three districts in the country. We have also joined a new project in Fiji headed by FijiStiftelsen. Thanks to the support of the W Initiative, FijiStiftelsen will be building two evacuation centres that will be used daily as a classroom and multipurpose room for children, as well as give women the opportunity to create their own workplace,” explains Boe Sletten.
Download pictures here: Pictures
More info here: https://www.w-initiative.com/en
W Initiative facts and figures
W Initiative is a newly established humanitarian foundation that aims to improve the quality of life of children and young people. The projects supported by the foundation may be in Norway or elsewhere but must always be grounded in UN Sustainable Development Goals 3, 4, 5, 6 or 10. The projects must have a focus on increased competence, better health, and more equal opportunities. Gustav Magnar Witzoe has donated NOK 110 million to the foundation through his family-owned company, of which NOK 100 million is earmarked for the foundation’s founding capital to enable increasingly meaningful contributions through effective management and expansion. The foundation will actively seek out projects that align with its vision and purpose and it will not be possible to apply for funding from the foundation. The foundation wishes to work together with well-established organisations. An annual report will be published on status and progress based on the foundation’s objectives.
Management board
Witzoe is the son of SalMar founder Gustav Witzoe and is currently the majority shareholder of the parent company Kvarv AS. The management board also includes NTNU professor Heri Ramampiaro, associate attorney Kristina Jorgensen, chief physician Elisabeth Vesterbekkmo and civil engineer Magnus Witzoe. All board members have a different background, but with a strong affiliation with Trondelag.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
